Medical Condition

solid tumor

Total Trials

37

Recruiting Now

37

Trial Phases

Phase 1, Phase 2, Phase 1, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for solid tumor sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — solid tumor Clinical Trials

How many clinical trials are currently recruiting for solid tumor?

ClinicalMetric currently tracks 37 actively recruiting clinical trials for solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 37. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for solid tumor?

solid tumor research spans Phase 1 (28 trials), Phase 2 (13 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a solid tumor clinical trial?

Eligibility criteria for solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Sichuan Baili Pharmaceutical Co., Ltd. 4 trials

St. Jude Children's Research Hospital 2 trials

Avelos Therapeutics Inc. 1 trial

Oxford BioTherapeutics Ltd 1 trial

Eisai Inc. 1 trial

solid tumor

Frequently Asked Questions — solid tumor Clinical Trials

Recruiting Clinical Trials

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Personalised Immunotherapy Platform

Ex Vivo Expansion (ACT-X)

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Autologous Tumour Vaccine Trial

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Immunotherapy for the Treatment of Advanced Solid Tumor

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

Clinical Study on Intraluminal Injection of FOLactis

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Psychotherapy Intervention for Latinos With Advanced Cancer

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Concurrent Azeliragon With Craniospinal Irradiation

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

DXP-106 in Solid Tumor Patients.

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Study of BM230 in Patients With Advanced Solid Tumors

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors